Purpose: To describe visual field (VF) outcomes in the Tube Versus Trabeculectomy (TVT) Study. Design: Cohort analysis of patients in a multicenter randomized clinical trial. Participants: A total of 122 eyes of 122 patients, with 61 eyes in both the tube shunt and trabeculectomy groups. Methods: The TVT Study is a multicenter randomized clinical trial comparing the safety and efficacy of tube shunt surgery (350-mm2 Baerveldt implant) and trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 4 minutes) in patients with previous cataract or glaucoma surgery. Enrolled patients underwent perimetry at baseline and annual follow-up visits. The VFs were included if the false-positive rate was ≤20% and false-negative rate was ≤35%. The VFs were excluded if visual acuity <20/400 or loss of ≥2 Snellen lines from baseline was attributed to an etiology other than glaucoma. Longitudinal linear mixed-effects models with best linear unbiased predictions (BLUPs) were applied to estimate rates of change in mean deviation (MD) for each treatment group. Main Outcome Measure: Rate of MD change during follow-up period. Results: A total of 436 reliable VFs were analyzed, with an average of 3.6 VFs per eye. Baseline MD was −13.07 ± 8.4 decibels (dB) in the tube shunt group and −13.18 ± 8.2 dB in the trabeculectomy group (P = 0.99). The rate of change in MD was −0.60 dB/year in the tube group and −0.38 dB/year in the trabeculectomy group (P = 0.34). The 95% confidence intervals for the rates of MD change were −0.77 to −0.44 dB/year in the tube group and −0.56 to −0.20 dB/year in the trabeculectomy group. No significant difference in MD slope was seen when patients were categorized by percentage of visits with intraocular pressure (IOP) <18 mmHg or by average IOP. Univariable and multivariable risk factor analyses identified history of diabetes, elevated IOP, and worse MD as baseline factors associated with more rapid VF loss. Conclusions: Slow rates of VF loss were observed after randomized surgical treatment in the TVT Study, but no significant difference in the rate of VF loss was seen after tube shunt implantation and trabeculectomy with MMC. Patients with diabetes, higher IOP, and more severe VF loss at baseline were at higher risk for VF progression.
ASJC Scopus subject areas